Similarly, we recently demonstrated that the parallel assessment of innate (CD47) and adaptive (PD-L1) immune checkpoints on CTCs has significant prognostic and predictive implications in breast cancer [39]. This evidence concerns the gene CD47 and breast carcinoma.